Events
Visitors to Island’s booth express their positive experiences with Island’s enterprise-level security solutions. They highlight how Island stands out by not only providing security but also enhancing productivity within the work environment.
Latest
Events
2023 Infosec Conversation with Ashley Brinsford
Ash and Ari discuss the upcoming Infosec event and the exciting developments since the previous year. Ash, the head of EMEA, shares the remarkable progress made by the go-to-market team, which has resulted in over 400 customer interactions and the transformation of previously deemed unsolvable projects into opportunities using the Island Enterprise Browser. The conversation…
Events
2023 Infosec Announcement with Bradon Rogers
Braden Rogers, Chief Customer Officer at Island, introduces the concept of reimagining the web browser for the enterprise. He highlights the common challenge of using consumer-oriented browsers for work purposes, which leads to complex infrastructure setups to ensure security. Island’s solution involves creating an enterprise browser compatible with Chrome and Edge. Braden invites viewers to…
Events
Island Booth Reactions
A compilation of our visitors’ reactions after engaging with the Island event trade booth. The video not only captures the booth’s visual allure but also the buzz of excitement and curiosity it generates. These reactions offer a glimpse into the booth’s ability to captivate, engage, and leave a lasting impression on event attendees.
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
